[1] Endometrial cancer and hormone-replacement therapy in the Million Women Study. The Lancet 2005;365:1543–51 10.1016/S0140-6736(05)66455-0

[2] DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994;13:1341-52; discussion 1353-6 10.1002/sim.4780131308 [7973215]

[3] Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 2016;387:1540–50 10.1016/S0140-6736(15)01281-7 [26712084]

[4] Boos CJ, Lip GYH. Ximelagatran: an eulogy. Thrombosis Research 2006;118:301–04 10.1016/j.thromres.2006.02.012 [16626788]

[5] Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 2021 10.1056/NEJMoa2110345 [34525277]

[6] Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2021;385:1078–90 10.1056/NEJMoa2110475 [34432976]

[7] Grant AM, Altman DG, Babiker AB et al. Issues in data monitoring and interim analysis of trials ;

[8] Bruyne B de, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991–1001 10.1056/NEJMoa1205361 [22924638]

[9] Jennison C, Turnbull BW. Statistical Approaches to Interim Monitoring of Medical Trials: A Review and Commentary. Statistical Science 1990;5:299–317 ;

[10] The coronary drug project. Design, methods, and baseline results. Circulation 1973;47:I1-50 10.1161/01.cir.47.3s1.i-1 [4570454]

[11] Jayk Bernal A, Da Gomes Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 2021 10.1056/NEJMoa2116044 [34914868]

[12] Anand SS, Wittes J, Yusuf S. What information should a sponsor of a randomized trial receive during its conduct? Clin Trials 2011;8:716–19 10.1177/1740774511424421 [22024103]

[13] Borer JS, Gordon DJ, Geller NL. When should data and safety monitoring committees share interim results in cardiovascular trials? JAMA 2008;299:1710–12 10.1001/jama.299.14.1710 [18398083]

[14] Ellenberg SS, Fleming TR, DeMets DL. Data monitoring in clinical trials: A practical perspective. Hoboken NJ: Wiley 2019 ISBN:9781119512653;

[15] Wayant C, Vassar M. A comparison of matched interim analysis publications and final analysis publications in oncology clinical trials. Annals of Oncology 2018;29:2384–90 10.1093/annonc/mdy447 [30307531]